Potential of long-chain n-3 polyunsaturated fatty acids in melanoma prevention

Nutrition Reviews

Volumn 72, Issue 4, 2014, Pages 255-266

  Serini, Simona ^a   Fasano, Elena ^a   Celleno, Leonardo ^a   Cittadini, Achille ^a   Calviello, Gabriella ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chemoprevention; Experimental studies; Fatty acids; Human studies; Long chain n 3 PUFA; Melanoma

Indexed keywords

LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; ANTINEOPLASTIC AGENT; EDIBLE OIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER THERAPY; HUMAN; IN VITRO STUDY; INTERVENTION STUDY; MEDICAL LITERATURE; MELANOMA; MOLECULAR MECHANICS; NONHUMAN; OBSERVATIONAL STUDY; APOPTOSIS; CELL CYCLE; DRUG EFFECTS; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DIETARY FATS, UNSATURATED; FATTY ACIDS, OMEGA-3; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

EID: 84898057095     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12093     Document Type: Article

References (121)

1. Siegel R, Ward E, Brawley O, etal. Cancer statistics, The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
2. Simard EP, Ward EM, Siegel R, etal. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118-128.
3. Jemal A, Siegel R, Ward E, etal. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
4. Slominski A, Wortsman J, Carlson AJ, etal. Malignant melanoma. Arch Pathol Lab Med. 2001;125:1295-1306.
5. Mukhtar H, Elmets CA. Photocarcinogenesis: mechanisms, models and human health implications. Photochem Photobiol. 1996;63:356-357.
6. Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res. 1993;3:395-401.
7. Kvaskoff M, Weinstein P. Are some melanomas caused by artificial light? Med Hypotheses. 2010;75:305-311.
8. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150:179-185.
9. Klinac D, Gray ES, Millward M, etal. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. doi: 10.3389/fonc.2013.00054.
10. Argiris K, Panethymitaki C, Tavassoli M. Naturally occurring, tumor-specific, therapeutic proteins. Exp Biol Med (Maywood). 2011;236:524-536.
11. Demierre MF, Nathanson L. Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol. 2003;21:158-165.
12. Calviello G, Serini S, Piccioni E, etal. Beneficial effects of n-3 PUFA on UV-induced skin damage and tumorigenesis. In: Heikkinen EP, ed. Fish Oils and Health. New York: Nova Science Publishers, Inc.; 2008:141-158.
13. Vanden Berghe W. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol Res. 2012;65:565-576.
14. Calviello G, Serini S, Palozza P. n-3 polyunsaturated fatty acids as signal transduction modulators and therapeutical agents in cancer. Curr Signal Transduct Ther. 2006;1:255-271.
15. Anti M, Marra G, Armelao F, etal. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology. 1992;103:883-891.
16. Anti M, Armelao F, Marra G, etal. Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology. 1994;107:1709-1718.
17. Calviello G, Di Nicuolo F, Gragnoli S, etal. n-3 PUFA reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis. 2004;25:2303-2310.
18. Calviello G, Di Nicuolo F, Serini S, etal. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol. 2005;55:12-20.
19. Calviello G, Resci F, Serini S, etal. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis. 2007;28:1202-1209.
20. Calviello G, Serini S, Piccioni E. n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved. Curr Med Chem. 2007;14:3059-3069.
21. Fasano E, Serini S, Piccioni E, etal. DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines. Biochim Biophys Acta. 2012;1822:1762-1772.
22. Serini S, Donato V, Piccioni E, etal. Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR. J Nutr Biochem. 2011;22:874-885.
23. Serini S, Fasano E, Piccioni E, etal. DHA induces apoptosis and differentiation in human melanoma cells in vitro: involvement of HuR-mediated COX-2 mRNA stabilization and β-catenin nuclear translocation. Carcinogenesis. 2012;33:164-173.
24. Miller AB, Gaudette LA. Cancers of skin, bone, connective tissues, brain, eye, thyroid and other specified and unspecified sites in Inuit. Acta Oncol. 1996;35:607-616.
25. Pilkington SM, Massey KA, Bennett SP, etal. Randomized controlled trial of oral omega-3 PUFA in solar-simulated radiation-induced suppression of human cutaneous immune responses. Am J Clin Nutr. 2013;97:646-652.
26. Black HS, Rhodes LE. The potential of omega-3 fatty acids in the prevention of non-melanoma skin cancer. Cancer Detect Prev. 2006;30:224-232.
27. Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2:355-374.
28. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170-1184.
29. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011;111:5922-5943.
30. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle. 2009;8:2005-2013.
31. Allavena P, Garlanda C, Borrello MG, etal. Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 2008;18:3-10.
32. Kim YS, Young MR, Bobe G, etal. Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res (Phila). 2009;2:200-208.
33. Navarini-Meury AA, Conrad C. Melanoma and innate immunity - active inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol. 2009;19:84-91.
34. Melnikova O, Bar-Eli M. Inflammation and melanoma metastasis. Pigment Cell Melanoma Res. 2009;22:257-267.
35. Meyer C, Sevko A, Ramacher M, etal. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A. 2011;108:17111-17116.
36. Sanz-Motilva V, Martorell-Calatayud A, Nagore E. Non-steroidal anti-inflammatory drugs and melanoma. Curr Pharm Des. 2012;18:3966-3978.
37. Simopoulos AP. Human requirement for N-3 polyunsaturated fatty acids. Poult Sci. 2000;79:961-970.
38. Blasbalg TL, Hibbeln JR, Ramsden CE, etal. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr. 2011;93:950-962.
39. Kuipers RS, Luxwolda MF, Dijck-Brouwer DA, etal. Estimated macronutrient and fatty acid intakes from an East African Paleolithic diet. Br J Nutr. 2010;104:1666-1687.
40. Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev. 2005;45:581-597.
41. Serini S, Innocenti I, Piccioni E, etal. The effects of omega-3 polyunsaturated fatty acids against cancer. In: Hermann W, Obeid R, eds. Vitamins in the Prevention of Human Diseases. Berlin: De Gruyter; 2010:679-696.
42. Serini S, Piccioni E, Calviello G. Dietary n-3 PUFA vascular targeting and the prevention of tumor growth and age-related macular degeneration. Curr Med Chem. 2009;16:4511-4526.
43. Serini S, Piccioni E, Merendino N, etal. Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis. 2009;14:135-152.
44. Serini S, Fasano E, Piccioni E, etal. Apoptosis as a mechanism involved in the anticancer effect of dietary n-3 polyunsaturated fatty acids. In: Chen GG, Lai PBS, eds. Novel Apoptotic Regulators in Carcinogenesis. Dordrecht, The Netherlands: Springer Science+Business Media; 2012:123-148.
45. Serini S, Fasano E, Piccioni E, etal. Differential anti-cancer effects of purified EPA and DHA and possible mechanisms involved. Curr Med Chem. 2011;18:4065-4075.
46. Gu Z, Suburu J, Chen H, etal. Mechanism of omega-3 polyunsaturated fatty acids in cancer prevention. Biomed Res Int. 2013. doi: 10.1155/2013/824563.
47. Mengeaud V, Nano JL, Fournel S, etal. Effects of eicosapentaenoic acid, gamma-linolenic acid and prostaglandin E1 on three human colon carcinoma cell lines. Prostaglandins Leukot Essent Fatty Acids. 1992;47:313-319.
48. Ng Y, Barhoumi R, Tjalkens RB, etal. The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis. 2005;26:1914-1921.
49. Dommels YE, Haring MM, Keestra NG, etal. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis. 2003;24:385-392.
50. Serini S, Fasano E, Piccioni E, etal. Dietary n-3 polyunsaturated fatty acids and the paradox of their health benefits and potential harmful effects. Chem Res Toxicol. 2011;24:2093-2105.
51. Siddiqui RA, Harvey KA, Zaloga GP, etal. Modulation of lipid rafts by omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support. Nutr Clin Pract. 2007;22:74-88.
52. Zhang G, Panigrahy D, Mahakian LM, etal. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A. 2013;110:6530-6535.
53. Im DS. Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res. 2012;51:232-237.
54. Reich R, Royce L, Martin GR. Eicosapentaenoic acid reduces the invasive and metastatic activities of malignant tumor cells. Biochem Biophys Res Commun. 1989;160:559-564.
55. Abbott WG, Tezabwala B, Bennett M, etal. Melanoma lung metastases and cytolytic effector cells in mice fed antioxidant-balanced corn oil or fish oil diets. Nat Immunol. 1994;13:15-28.
56. Salem ML, Kishihara K, Abe K, etal. N-3 polyunsaturated fatty acids accentuate B16 melanoma growth and metastasis through suppression of tumoricidal function of T cells and macrophages. Anticancer Res. 2000;20:3195-3203.
57. Browning LM, Walker CG, Mander AP, etal. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr. 2012;96:748-758.
58. Albino AP, Juan G, Traganos F, etal. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Cancer Res. 2000;60:4139-4145.
59. Cario-André M, Briganti S, Picardo M, etal. Polyunsaturated fatty acids partially reproduce the role of melanocytes in the epidermal melanin unit. Exp Dermatol. 2005;14:194-201.
60. Tezabwala BU, Bennett M, Grundy SM. Immunotoxicity of polyunsaturated fatty acids in serum-free medium. Immunopharmacol Immunotoxicol. 1995;17:365-383.
61. Denkins Y, Kempf D, Ferniz M, etal. Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma. J Lipid Res. 2005;46:1278-1284.
62. Ishikawa M, Fernandez B, Kerbel RS. Highly pigmented human melanoma variant which metastasizes widely in nude mice, including to skin and brain. Cancer Res. 1988;48:4897-4903.
63. Sengupta S, Jang BC, Wu MT, etal. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem. 2003;278:25227-25233.
64. Weylandt KH, Kang JX. Rethinking lipid mediators. Lancet. 2005;366:618-620.
65. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 2007;26:525-534.
66. Chakraborti AK, Garg SK, Kumar R, etal. Progress in COX-2 inhibitors: a journey so far. Curr Med Chem. 2010;17:1563-1593.
67. Horst D, Reu S, Kriegl L, etal. The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer. 2009;115:2063-2070.
68. Elzagheid A, Buhmeida A, Korkeila E, etal. Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol. 2008;14:3866-3871.
69. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer. 2000;36:664-674.
70. Emanuele S, D'Anneo A, Bellavia G, etal. Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/caspase pathway, associated with degradation of beta-catenin, pRb and Bcl-XL. Eur J Cancer. 2004;40:1441-1452.
71. Bordonaro M, Lazarova DL, Augenlicht LH, etal. Cell type- and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate. Int J Cancer. 2002;97:42-51.
72. Efstathiou JA, Noda M, Rowan A, etal. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci U S A. 1998;95:3122-3127.
73. Jaiswal AS, Marlow BP, Gupta N, etal. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene. 2002;21:8414-8427.
74. Carter O, Bailey GS, Dashwood RH. The dietary phytochemical chlorophyllin alters E-cadherin and beta-catenin expression in human colon cancer cells. J Nutr. 2004;134 (Suppl 12):S3441-S3444.
75. Calviello G, Di Nicuolo F, Piccioni E, etal. Gamma-tocopheryl quinone induces apoptosis in cancer cells via caspase-9 activation and cytochrome c release. Carcinogenesis. 2003;24:427-433.
76. Morin PJ, Sparks AB, Korinek V, etal. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787-1790.
77. Bachmann IM, Straume O, Puntervoll HE, etal. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res. 2005;11:8606-8614.
78. Chien AJ, Moore EC, Lonsdorf AS, etal. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A. 2009;106:1193-1198.
79. Sertznig P, Dunlop T, Seifert M, etal. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Anticancer Res. 2009;29:3647-3658.
80. Garneau V, Rudkowska I, Paradis AM, etal. Omega-3 fatty acids status in human subjects estimated using a food frequency questionnaire and plasma phospholipid levels. Nutr J. 2012;11:46. doi: 10.1186/1475-2891-11-46.
81. Zand H, Rhimipour A, Bakhshayesh M, etal. Involvement of PPAR-gamma and p53 in DHA-induced apoptosis in Reh cells. Mol Cell Biochem. 2007;304:71-77.
82. Mannini A, Kerstin N, Calorini L, etal. An enhanced apoptosis and a reduced angiogenesis are associated with the inhibition of lung colonisation in animals fed an n-3 polyunsaturated fatty acid-rich diet injected with a highly metastatic murine melanoma line. Br J Nutr. 2009;101:688-693.
83. Goldfarb Y, Shapiro H, Singer P, etal. Fish oil attenuates surgery-induced immunosuppression, limits post-operative metastatic dissemination and increases long-term recurrence-free survival in rodents inoculated with cancer cells. Clin Nutr. 2012;31:396-404.
84. Xia S, Lu Y, Wang J, etal. Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A. 2006;103:12499-12504.
85. Kang JX, Wang J, Wu L, etal. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature. 2004;427:504. doi:10.1038/427504a.
86. Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie. 2009;91:791-795.
87. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003;22:3113-3122.
88. Calviello G, Serini S, Piccioni E, etal. Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer. 2009;61:287-301.
89. Baumgartner M, Sturlan S, Roth E, etal. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer. 2004;112:707-712.
90. Chiu LC, Tong KF, Ooi VE. Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother. 2005;59 (Suppl 2):S293-S297.
91. Sauer LA, Nagel WO, Dauchy RT, etal. Stimulation of tumor growth in adult rats in vivo during an acute fast. Cancer Res. 1986;46:3469-3475.
92. Sauer LA, Dauchy RT. The effect of ω-6 and ω-3 fatty acids on 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ. Br J Cancer. 1992;66:297-303.
93. Bradley MO, Webb NL, Anthony FH, etal. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res. 2001;7:3229-3238.
94. Wang Y, Li L, Jiang W, etal. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett. 2006;16:2974-2977.
95. Kocak N, Ustün H, Gülkaç MD, etal. Effects of 10alpha, 25-dihydroxyvitamin D3 on doxorubicin-induced chromosomal aberrations in rat bone marrow cells. Acta Oncol. 2004;43:204-208.
96. Morelli D, Ménard S, Colnaghi MI, etal. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res. 1996;56:2082-2085.
97. Breyer S, Effenberger K, Schobert R. Effects of thymoquinone-fatty acid conjugates on cancer cells. ChemMedChem. 2009;4:761-768.
98. Woo CC, Kumar AP, Sethi G, etal. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012;83:443-451.
99. Wagner RF, DiSorbo DM, Nathanson L. Nutrition and melanoma. Int J Dermatol. 1984;23:453-457.
100. Mackie BS, Mackie LE, Curtin LD, etal. Melanoma and dietary lipids. Nutr Cancer. 1987;9:219-226.
101. English DR, Heenan PJ, Holman CD, etal. Melanoma in Western Australia 1975-76 to 1980-81: trends in demographic and pathological characteristics. Int J Cancer. 1986;37:209-215.
102. Gallagher RP, Elwood JM, Hill GB. Risk factors for cutaneous malignant melanoma: the Western Canada Melanoma Study. Recent Results Cancer Res. 1986;102:38-55.
103. Holman CD, Armstrong BK, Heenan PJ, etal. The causes of malignant melanoma: results from the West Australian Lions Melanoma Research Project. Recent Results Cancer Res. 1986;102:18-37.
104. Osterlind A, Tucker MA, Stone BJ, etal. The Danish case-control study of cutaneous malignant melanoma: IV. No association with nutritional factors, alcohol, smoking or hair dyes. Int J Cancer. 1988;42:825-828.
105. Kirkpatrick CS, White E, Lee JA. Case-control study of malignant melanoma in Washington State: II. Diet, alcohol, and obesity. Am J Epidemiol. 1994;139:869-880.
106. Bain C, Green A, Siskind V, etal. Diet and melanoma. An exploratory case-control study. Ann Epidemiol. 1993;3:235-238.
107. Kris-Etherton PM, Harris WS, Appel LJ, AHA Nutrition Committee. American Heart Association. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151-152.
108. Hamilton MC, Hites RA, Schwager SJ, etal. Lipid composition and contaminants in farmed and wild salmon. Environ Sci Technol. 2005;39:8622-8629.
109. Serini S, Piccioni E, Rinaldi C, etal. Fish from an artificial lake: n-3 PUFA content and chemical-physical and ecological features of the lake. J Food Compost Anal. 2010;23:133-141.
110. Pereira H, Barreira L, Figueiredo F, etal. Polyunsaturated fatty acids of marine macroalgae: potential for nutritional and pharmaceutical applications. Mar Drugs. 2012;10:1920-1935.
111. Lenihan-Geels G, Bishop KS, Ferguson LR. Alternative sources of omega-3 fats: can we find a sustainable substitute for fish? Nutrients. 2013;5:1301-1315.
112. Fracasso PM, Picus J, Wildi JD, etal. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2009;63:451-458.
113. Homsi J, Bedikian AY, Kim KB, etal. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res. 2009;19:238-242.
114. Homsi J, Bedikian AY, Papadopoulos NE, etal. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. 2010;20:507-510.
115. Bedikian AY, DeConti RC, Conry R, etal. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22:787-793.
116. Freireich EJ, Gehan EA, Rall DP, etal. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219-244.
117. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol. 2006;17:735-749.
118. Bougnoux P, Hajjaji N, Ferrasson MN, etal. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer. 2009;101:1978-1985.
119. West NJ, Clark SK, Phillips RK, etal. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. 2010;59:918-925.
120. Narayanan BA, Narayanan NK, Desai D, etal. Effects of a combination of docosahexaenoic acid and 1, 4-phenylene bis(methylene)selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells. Carcinogenesis. 2004;25:2443-2449.
121. Lim K, Han C, Dai Y, etal. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther. 2009;8:3046-3055.